不可切除Ⅲ期非小细胞肺癌的治疗原则及问题.pptVIP

/ Purpose This is a national, randomized, web-based, double-blind study to determine whether erlotinib (Tarceva) compared to placebo improves progression-free survival (PFS) for patients with inoperable, stage III NSCLC following concurrent docetaxel, carboplatin and thoracic radiotherapy. We hypothesize that the introduction of this orally active, well-tolerated agent following concurrent chemoradiation and prior to the emergence of drug resistance will prolong the progression-free survival by 40% (10 months → 14 months). Estimated Enrollment: 380 Study Start Date: May 2005 Estimated Study C